Quantum-Si Incorporated Dossier
Qualitative Analysis
Business overview
Quantum-Si Inc. (NASDAQ: QSI) is an innovative life sciences company focused on revolutionizing the field of proteomics through next-generation protein sequencing (NGPS). Founded in 2013 by Dr. Jonathan M. Rothberg, the company has developed a proprietary universal single-molecule detection platform that leverages semiconductor chip technology to sequence proteins in a massively parallel fashion. Its core commercial offerings include the Platinum and Platinum Pro benchtop instruments, which utilize time-domain sequencing to read kinetic signatures of amino acid binders, alongside specialized consumables, sequencing kits, and cloud-based analysis software. By shifting protein sequencing from complex, centralized core facilities to accessible benchtop workflows, Quantum-Si aims to democratize proteomics for academic, biopharma, and clinical research.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing all research, development, and engineering resources to complete the systems integration, manufacturing transfer, and production ramp of the next-generation Proteus proteomics platform.
Expected impact: Positions the company to capture the premium value of single-molecule protein sequencing with a platform designed to far exceed the performance of the first-generation Platinum Pro system.
Offering flexible instrument acquisition options, including placement programs and embedding upgrade credits into Platinum Pro units sold in 2026, to provide customers with a clear path to transition to Proteus.
Expected impact: Expands the active customer base, drives immediate consumable utilization, and prepares the market for rapid adoption of the Proteus platform upon launch.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating to develop and validate approaches for protein sequencing and post-translational modification (PTM) analysis on the Proteus platform, leveraging CST's antibody and assay expertise.
Terms: Terms of the agreement were not publicly disclosed.
Expanded partnership where Planet Innovation serves as the contract manufacturing partner for the Platinum Pro instrument and supports the development and manufacturing transition of the Proteus platform.
Terms: Terms of the agreement were not publicly disclosed.